BACKGROUND: Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on intraplantar administration of cisplatin and oxaliplatin and to systematically evaluate the analgesic efficacy of a range of therapeutics. METHODS: Neuropathy was induced by a single intraplantar injection of cisplatin or oxaliplatin in C57BL/6J mice and assessed by quantification of mechanical and thermal allodynia. The pharmacological basis of cisplatin-induced neuropathy was characterized using a range of selective pharmacological inhibitors. The analgesic effects of phenytoin, amitriptyline, oxcarbazepine, mexiletine, topiramate, retigabine, gabapentin, fentanyl, and Ca(2+/)Mg(2+) were assessed 24 hours after induction of neuropathy. RESULTS: Intraplantar administration of cisplatin led to the development of mechanical allodynia, mediated through Nav1.6-expressing sensory neurons. Unlike intraplantar injection of oxaliplatin, cold allodynia was not observed with cisplatin, consistent with clinical observations. Surprisingly, only fentanyl was effective at alleviating cisplatin-induced mechanical allodynia despite a lack of efficacy in oxaliplatin-induced cold allodynia. Conversely, lamotrigine, phenytoin, retigabine, and gabapentin were effective at reversing oxaliplatin-induced cold allodynia but had no effect on cisplatin-induced mechanical allodynia. Oxcarbazepine, amitriptyline, mexiletine, and topiramate lacked efficacy in both models of acute chemotherapy-induced neuropathy. CONCLUSION: This study established a novel animal model of cisplatin-induced mechanical allodynia consistent with the A-fiber neuropathy seen clinically. Systematic assessment of a range of therapeutics identified several candidates that warrant further clinical investigation.
BACKGROUND:Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on intraplantar administration of cisplatin and oxaliplatin and to systematically evaluate the analgesic efficacy of a range of therapeutics. METHODS:Neuropathy was induced by a single intraplantar injection of cisplatin or oxaliplatin in C57BL/6J mice and assessed by quantification of mechanical and thermal allodynia. The pharmacological basis of cisplatin-induced neuropathy was characterized using a range of selective pharmacological inhibitors. The analgesic effects of phenytoin, amitriptyline, oxcarbazepine, mexiletine, topiramate, retigabine, gabapentin, fentanyl, and Ca(2+/)Mg(2+) were assessed 24 hours after induction of neuropathy. RESULTS: Intraplantar administration of cisplatin led to the development of mechanical allodynia, mediated through Nav1.6-expressing sensory neurons. Unlike intraplantar injection of oxaliplatin, cold allodynia was not observed with cisplatin, consistent with clinical observations. Surprisingly, only fentanyl was effective at alleviating cisplatin-induced mechanical allodynia despite a lack of efficacy in oxaliplatin-induced cold allodynia. Conversely, lamotrigine, phenytoin, retigabine, and gabapentin were effective at reversing oxaliplatin-induced cold allodynia but had no effect on cisplatin-induced mechanical allodynia. Oxcarbazepine, amitriptyline, mexiletine, and topiramate lacked efficacy in both models of acute chemotherapy-induced neuropathy. CONCLUSION: This study established a novel animal model of cisplatin-induced mechanical allodynia consistent with the A-fiber neuropathy seen clinically. Systematic assessment of a range of therapeutics identified several candidates that warrant further clinical investigation.
Authors: Jennifer R Deuis; Katharina Zimmermann; Andrej A Romanovsky; Lourival D Possani; Peter J Cabot; Richard J Lewis; Irina Vetter Journal: Pain Date: 2013-05-24 Impact factor: 6.961
Authors: Susanna B Park; Cindy S-Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan Journal: Brain Date: 2009-09-10 Impact factor: 13.501
Authors: Jacob A Vincent; Krystyna B Wieczerzak; Hanna M Gabriel; Paul Nardelli; Mark M Rich; Timothy C Cope Journal: Neurobiol Dis Date: 2016-07-07 Impact factor: 5.996
Authors: Luke G McVeigh; Anthony J Perugini; Jill C Fehrenbacher; Fletcher A White; Melissa A Kacena Journal: Curr Osteoporos Rep Date: 2020-10 Impact factor: 5.096
Authors: Hana Starobova; Mercedes Monteleone; Christelle Adolphe; Lena Batoon; Cheyenne J Sandrock; Bryan Tay; Jennifer R Deuis; Alexandra V Smith; Alexander Mueller; Evelyn Israel Nadar; Grace Pamo Lawrence; Amanda Mayor; Elissa Tolson; Jean-Pierre Levesque; Allison R Pettit; Brandon J Wainwright; Kate Schroder; Irina Vetter Journal: J Exp Med Date: 2021-05-03 Impact factor: 14.307
Authors: Jennifer R Deuis; Zoltan Dekan; Joshua S Wingerd; Jennifer J Smith; Nehan R Munasinghe; Rebecca F Bhola; Wendy L Imlach; Volker Herzig; David A Armstrong; K Johan Rosengren; Frank Bosmans; Stephen G Waxman; Sulayman D Dib-Hajj; Pierre Escoubas; Michael S Minett; Macdonald J Christie; Glenn F King; Paul F Alewood; Richard J Lewis; John N Wood; Irina Vetter Journal: Sci Rep Date: 2017-01-20 Impact factor: 4.379